Organs-on-Chips: Revolutionizing Biomedical Research

Organs-on-Chips (OoC) technology has begun to be considered a pragmatic tool for drug evaluation, offering researchers an opportunity to move beyond the less physiologically relevant animal models. OoCs are microfluidic structures that imitate the functionalities of individual human organs, serving as mimicry tools for drug response and reproducibility studies. On the one hand, companies producing OoCs find managing and analyzing the large amounts of data generated challenging. This is where artificial intelligence (AI) can be deployed to address such problems. This paper will present the state-of-the-art of current OoC technology and AI, discussing the benefits and threats of combining these approaches. AI can be applied to optimize the process of OoC fabrication and operation, as well as for the big data analysis of OoC devices. By combining these technologies, scientists gain a powerful tool for drug development that is more efficient and accurate. However, processing the vast datasets generated by OoC systems often requires specialized AI expertise and computational resources. Despite the numerous possible benefits of amalgamating OoC technology with AI, several challenges and limitations need to be addressed. The large datasets generated by OoC systems can be difficult to process and analyze, which is a task that may require specialized AI expertise. Additionally, limitations of OoC systems include issues with reproducibility, as the devices are sensitive to perturbations in experimental conditions. Furthermore, the development and implementation of AI algorithms require significant computational resources and expertise, which may not be readily available to all research institutions. To overcome these challenges, interdisciplinary collaboration between biologists, engineers, data scientists, and AI experts is essential. Continued advancements in both OoC technology and AI will likely lead to more robust and versatile platforms for biomedical research and drug development, ultimately contributing to the advancement of personalized medicine and the reduction of reliance on animal testing.